Sign In
Buy ERAS
$13.67
-0.310 (-2.22%)
At Close: Jun 18, 2026
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
01:30am, Monday, 20'th May 2024
SolStock Deals and Financings Japan’s Takeda (TAK, OTCPK:TKPHF; TSE: 4502) acquired global rights to an Alzheimer’s therapy developed by AC Immune SA (ACIU) of Switzerland for $100 million upfront
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
08:02pm, Thursday, 16'th May 2024
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors
Erasca Announces Pricing of Underwritten Offering of Common Stock
08:00pm, Thursday, 16'th May 2024
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa
Erasca Reports First Quarter 2024 Business Updates and Financial Results
04:01pm, Wednesday, 08'th May 2024
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and exist
Erasca to Present at the Bank of America Health Care Conference
08:00am, Tuesday, 07'th May 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
04:05pm, Wednesday, 24'th Apr 2024
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 23'rd Apr 2024
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for April 23rd
11:01am, Tuesday, 23'rd Apr 2024
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.
New Strong Buy Stocks for April 23rd
08:16am, Tuesday, 23'rd Apr 2024
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
11:11am, Friday, 29'th Mar 2024
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
Erasca Announces $45 Million Oversubscribed Private Placement Financing
08:30pm, Wednesday, 27'th Mar 2024
Funding from new and existing investors extends anticipated cash runway into H2 2026 Funding from new and existing investors extends anticipated cash runway into H2 2026
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
04:01pm, Wednesday, 27'th Mar 2024
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 03'rd Jan 2024
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
3 Penny Stocks You'll Regret Not Buying Soon: December Edition
01:34pm, Wednesday, 20'th Dec 2023
Although extremely risky, penny stocks can provide tactical value to a portfolio. The risk of losing it all is very real.
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
08:00am, Monday, 11'th Dec 2023
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safet
